Suppr超能文献

接受阿托品治疗的近视儿童的眼压趋势

Intraocular Pressure Trends in Children with Myopia Receiving Atropine Therapy.

作者信息

Hsia Yun, Chen Pao-Ju, Ma I-Hsin, Lee Yi-Chieh, Tsai Tzu-Hsun

机构信息

Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

出版信息

Ophthalmol Ther. 2025 Sep 19. doi: 10.1007/s40123-025-01243-7.

Abstract

INTRODUCTION

Topical atropine is widely used for myopia control in children, with proven efficacy in slowing myopia progression. However, concerns remain regarding its potential effects on intraocular pressure (IOP), particularly with long-term use. This study aimed to evaluate the longitudinal effects of topical atropine on IOP in children with myopia.

METHODS

This retrospective, longitudinal study enrolled children using 0.125% atropine to control myopia progression and atropine non-users. IOP was measured repeatedly before and during treatment. RTVue optical coherence tomography (OCT) measured retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness. Multilevel models assessed IOP changes by adjusting age, sex, spherical equivalent, central corneal thickness, and baseline IOP.

RESULTS

A total of 188 patients (376 eyes) in the atropine group and 188 patients (376 eyes) in the control group were included. There were 86 boys (46%) aged 8.0 ± 2.5 years. Patients in the atropine group were more myopic (-1.17 ± 1.40 versus 0.73 ± 1.83 D, P < 0.001). The central corneal thickness and baseline IOP (atropine: 17.6 ± 3.0 mmHg; control: 17.2 ± 3.6 mmHg) were similar. Over a follow-up of 18.6 months (atropine, 19.3 months; control, 18.0 months), the final IOP was higher in the atropine group (18.3 ± 3.6 versus 16.7 ± 3.2 mmHg, P < 0.001). In the multivariable multilevel models, atropine was associated with an additional 0.51-mmHg increase (95% confidence interval [CI] 0.36-0.67, P = 0.001) in IOP per year when adjusted for sex, age, central corneal thickness, spherical equivalent, and baseline IOP. RNFL (104.0 ± 8.8 versus 102.6 ± 7.5 µm, P = 0.475) and GCC thickness (98.1 ± 5.6 versus 96.7 ± 5.8 µm, P = 0.270) showed no significant differences between groups.

CONCLUSIONS

Atropine use for myopia control in children was associated with a modest IOP increase without apparent impact on RNFL. Regular IOP monitoring is advisable.

摘要

引言

局部用阿托品广泛用于儿童近视控制,在减缓近视进展方面已证实有效。然而,其对眼压(IOP)的潜在影响仍令人担忧,尤其是长期使用时。本研究旨在评估局部用阿托品对近视儿童眼压的纵向影响。

方法

这项回顾性纵向研究纳入了使用0.125%阿托品控制近视进展的儿童以及未使用阿托品的儿童。在治疗前和治疗期间反复测量眼压。RTVue光学相干断层扫描(OCT)测量视网膜神经纤维层(RNFL)和神经节细胞复合体(GCC)厚度。多水平模型通过调整年龄、性别、等效球镜度、中央角膜厚度和基线眼压来评估眼压变化。

结果

阿托品组共纳入188例患者(376只眼),对照组纳入188例患者(376只眼)。有86名男孩(46%),年龄8.0±2.5岁。阿托品组患者近视程度更高(-1.17±1.40 D对0.73±1.83 D,P<0.001)。中央角膜厚度和基线眼压(阿托品组:17.6±3.0 mmHg;对照组:17.2±3.6 mmHg)相似。在18.6个月的随访期内(阿托品组19.3个月,对照组18.0个月),阿托品组的最终眼压更高(18.3±3.6 mmHg对16.7±3.2 mmHg,P<0.001)。在多变量多水平模型中,调整性别、年龄、中央角膜厚度、等效球镜度和基线眼压后,阿托品使用与眼压每年额外升高0.51 mmHg相关(95%置信区间[CI] 0.36 - 0.67,P = 0.001)。RNFL厚度(104.0±8.8 µm对102.6±7.5 µm,P = 0.475)和GCC厚度(98.1±5.6 µm对96.7±5.8 µm,P = 0.270)在两组间无显著差异。

结论

儿童使用阿托品控制近视与眼压适度升高相关,但对RNFL无明显影响。建议定期监测眼压。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验